NEFM抗体

+ +

•  

   

     Western blot analysis of CD276 in HepG2 lysates using CD276 antibody.    

  
  

Neurofilament medium (NEFM) antibodies are essential tools in neuroscience research, targeting the intermediate filament protein NEFM, a key component of the neuronal cytoskeleton. Neurofilaments (NFs), composed of three subunits—NEFL (light), NEFM (medium), and NEFH (heavy)—play critical roles in maintaining axonal structural integrity, regulating diameter, and facilitating intracellular transport. NEFM, with its central rod domain and variable phosphorylation sites, contributes to NF assembly and stability, influencing neuronal morphology and function.

NEFM antibodies are widely used to study neuronal development, degeneration, and injury. In pathological contexts, elevated NEFM levels in cerebrospinal fluid (CSF) or blood serve as biomarkers for axonal damage in neurodegenerative diseases (e.g., ALS, Alzheimer’s, Parkinson’s) and neurotrauma (e.g., stroke, multiple sclerosis). These antibodies help detect NF breakdown products, reflecting disease progression or therapeutic response. Additionally, NEFM expression patterns aid in mapping neuronal subtypes and understanding neurodevelopmental disorders.

Research also explores NEFM's phosphorylation dynamics, which modulate NF interactions and axonal transport. Commercial NEFM antibodies are validated for techniques like immunohistochemistry, Western blotting, and ELISA, though specificity challenges due to cross-reactivity with other NF subunits require careful validation. Overall, NEFM antibodies bridge basic neurobiology and clinical diagnostics, offering insights into both physiological and pathological neural processes.